SG11201509463YA - 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection - Google Patents

6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection

Info

Publication number
SG11201509463YA
SG11201509463YA SG11201509463YA SG11201509463YA SG11201509463YA SG 11201509463Y A SG11201509463Y A SG 11201509463YA SG 11201509463Y A SG11201509463Y A SG 11201509463YA SG 11201509463Y A SG11201509463Y A SG 11201509463YA SG 11201509463Y A SG11201509463Y A SG 11201509463YA
Authority
SG
Singapore
Prior art keywords
heteroaryldihydropyrimidines
prophylaxis
bridged
hepatitis
treatment
Prior art date
Application number
SG11201509463YA
Inventor
Lei Guo
taishan Hu
Yimin Hu
Buelent Kocer
Buyu Kou
Gangqin Li
Xianfeng Lin
Haixia Liu
Hong Shen
Houguang Shi
Guolong Wu
Zhisen Zhang
Mingwei Zhou
Wei Zhu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50733070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201509463Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201509463YA publication Critical patent/SG11201509463YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
SG11201509463YA 2013-05-17 2014-05-16 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection SG11201509463YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2013075815 2013-05-17
CN2014075392 2014-04-15
PCT/EP2014/060034 WO2014184328A1 (en) 2013-05-17 2014-05-16 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection

Publications (1)

Publication Number Publication Date
SG11201509463YA true SG11201509463YA (en) 2015-12-30

Family

ID=50733070

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201509463YA SG11201509463YA (en) 2013-05-17 2014-05-16 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection

Country Status (18)

Country Link
US (2) US9266904B2 (en)
EP (1) EP2997032B1 (en)
JP (1) JP6533217B2 (en)
CN (1) CN105209470B (en)
AU (1) AU2014267198A1 (en)
BR (1) BR112015028873A2 (en)
CA (1) CA2911214A1 (en)
CL (1) CL2015003298A1 (en)
CR (1) CR20150611A (en)
EA (1) EA201592126A1 (en)
HK (1) HK1219480A1 (en)
MX (1) MX2015015692A (en)
PE (1) PE20151951A1 (en)
PH (1) PH12015502443A1 (en)
SG (1) SG11201509463YA (en)
TW (1) TW201512193A (en)
WO (1) WO2014184328A1 (en)
ZA (1) ZA201507840B (en)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090044A1 (en) 2011-12-21 2014-10-15 Novira Therapeutics Inc ANTIVIRAL AGENTS FOR HEPATITIS B
TWI636036B (en) 2012-08-28 2018-09-21 健生科學愛爾蘭無限公司 Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
PE20150776A1 (en) * 2012-09-10 2015-05-21 Hoffmann La Roche 6-AMINO ACID-HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
EP2961732B1 (en) 2013-02-28 2017-04-12 Janssen Sciences Ireland UC Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
EA027068B1 (en) 2013-04-03 2017-06-30 Янссен Сайенсиз Айрлэнд Юси N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JP6533217B2 (en) * 2013-05-17 2019-06-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 6-Bridged Heteroaryldihydropyrimidines for the Treatment and Prevention of Hepatitis B Virus Infection
SI3231801T1 (en) 2013-05-17 2019-05-31 Incyte Corporation Bipyrazole salt as jak inhibitor
HUE040446T2 (en) 2013-05-17 2019-03-28 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US10450270B2 (en) 2013-07-25 2019-10-22 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
MX368158B (en) 2013-10-23 2019-09-20 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b.
CN104650068B (en) 2013-11-19 2018-08-10 广东东阳光药业有限公司 Dihydropyrimidines and its application in drug
WO2015078392A1 (en) 2013-11-27 2015-06-04 Sunshine Lake Pharma Co., Ltd. Processes for preparing dihydropyrimidine derivatives and intermediates thereof
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JP6553059B2 (en) 2014-02-05 2019-07-31 ノヴィラ・セラピューティクス・インコーポレイテッド Combination therapy for the treatment of HBV infection
EA035848B1 (en) 2014-02-06 2020-08-20 Янссен Сайенсиз Айрлэнд Юси Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
EP3114128B1 (en) 2014-03-07 2019-01-02 F. Hoffmann-La Roche AG Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN110437153A (en) 2014-03-13 2019-11-12 美国印第安纳大学研究和技术公司 Hepatitis B virus allosteric modulators
EP3122747B1 (en) 2014-03-28 2020-05-20 North & South Brother Pharmacy Investment Company Limited Dihydropyrimidine compounds and their application in pharmaceuticals
WO2016102438A1 (en) * 2014-12-23 2016-06-30 F. Hoffmann-La Roche Ag Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine analogues
CN105859709B (en) 2015-02-07 2018-12-04 广东东阳光药业有限公司 The compound of dihydropyrimidine derivatives and its application in drug
SI3321265T1 (en) 2015-03-04 2020-07-31 Gilead Sciences, Inc. 4,6-diamino-pyrido(3,2-d)pyrimidine compounds and their utilisation as modulators of toll-like receptors
MA52701A (en) * 2015-03-16 2021-03-31 Hoffmann La Roche COMBINATION WITH TLR7 AGONIST AND HEPATITIS B VIRUS CAPSIDE ASSEMBLY INHIBITOR
WO2016161268A1 (en) 2015-04-01 2016-10-06 Enanta Pharmaceuticals, Inc. Hepatitis b antviral agents
CN106146327B (en) * 2015-04-03 2019-03-19 浙江海正药业股份有限公司 A kind of synthetic method of D-Cycloserine intermediate
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017011552A1 (en) 2015-07-13 2017-01-19 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US10301255B2 (en) 2015-07-22 2019-05-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
MA42684A (en) 2015-08-26 2018-07-04 Gilead Sciences Inc TOLL RECEIVER DEUTERATED MODULATORS
TWI721016B (en) 2015-09-15 2021-03-11 美商艾森伯利生物科學公司 Hepatitis b core protein modulators
MX2018005230A (en) * 2015-11-03 2018-08-15 Hoffmann La Roche Combination therapy of an hbv capsid assembly inhibitor and an interferon.
WO2017108630A1 (en) * 2015-12-21 2017-06-29 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor
WO2017136403A1 (en) * 2016-02-02 2017-08-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
AR107633A1 (en) 2016-02-19 2018-05-16 Hoffmann La Roche PROCEDURE FOR THE PREPARATION OF ACID 4-PHENYL-5-ALCOXICARBONIL-2-TIAZOL-2-IL-1,4-DIHYDROPIRIMIDIN-6-IL- [METHYL] -3-OXO-5,6,8,8A-TETRAHIDRO- 1H-IMIDAZO [1,5A] PIRAZIN-2-IL-CARBOXYL
KR102398439B1 (en) 2016-03-07 2022-05-16 이난타 파마슈티칼스, 인코포레이티드 Hepatitis B antiviral drugs
US10441589B2 (en) 2016-04-15 2019-10-15 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
WO2017198744A1 (en) * 2016-05-20 2017-11-23 F. Hoffmann-La Roche Ag Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases
MX2018014377A (en) 2016-05-27 2019-03-14 Gilead Sciences Inc Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors.
BR102017010009A2 (en) 2016-05-27 2017-12-12 Gilead Sciences, Inc. COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION
CN109843296A (en) * 2016-06-10 2019-06-04 英安塔制药有限公司 B type hepatitis antivirus medicament
WO2018036941A1 (en) 2016-08-24 2018-03-01 F. Hoffmann-La Roche Ag Combination therapy of an hbv capsid assembly inhibitor and a nucleos(t)ide analogue
JOP20190024A1 (en) 2016-08-26 2019-02-19 Gilead Sciences Inc Substituted pyrrolizine compounds and uses thereof
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
PT3507276T (en) 2016-09-02 2022-01-11 Gilead Sciences Inc Toll like receptor modulator compounds
WO2018045911A1 (en) * 2016-09-09 2018-03-15 浙江海正药业股份有限公司 Dihydropyrimidines, preparation method and use thereof
EP3512556B1 (en) 2016-09-13 2021-08-18 F. Hoffmann-La Roche AG Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
WO2018053157A1 (en) 2016-09-15 2018-03-22 Assembly Biosciences, Inc. Hepatitis b core protein modulators
KR102305215B1 (en) 2016-10-14 2021-09-28 프리시젼 바이오사이언시스 인코포레이티드 Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
US11166954B2 (en) 2016-11-18 2021-11-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Dihydropyrimidine compound and preparation method and use thereof
ES2901401T3 (en) 2016-11-18 2022-03-22 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Dihydropyrimidine compound and method of preparation and use thereof
TW202402300A (en) 2017-01-31 2024-01-16 美商基利科學股份有限公司 Crystalline forms of tenofovir alafenamide
JOP20180008A1 (en) 2017-02-02 2019-01-30 Gilead Sciences Inc Compounds for the treatment of hepatitis b virus infection
ES2898217T3 (en) 2017-03-02 2022-03-04 Assembly Biosciences Inc Cyclic sulfonamide compounds and methods of using the same
JOP20180040A1 (en) 2017-04-20 2019-01-30 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
US11142527B2 (en) 2017-06-26 2021-10-12 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and uses thereof in medicine
JP2020525490A (en) 2017-06-27 2020-08-27 ヤンセン ファーマシューティカ エヌ．ベー． Heteroaryldihydropyrimidine derivatives and methods for treating hepatitis B infection
JP6934562B2 (en) 2017-08-22 2021-09-15 ギリアード サイエンシーズ， インコーポレイテッド Therapeutic heterocyclic compounds
CN111263586B (en) 2017-08-28 2021-12-03 英安塔制药有限公司 Hepatitis B antiviral agent
US11261190B2 (en) 2017-10-18 2022-03-01 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and uses thereof in medicine
EA202091113A1 (en) 2017-11-02 2020-08-28 Айкурис Гмбх Унд Ко. Кг NEW HIGHLY ACTIVE AMINOTHIAZOL SUBSTITUTED INDOL-2-CARBOXAMIDES ACTIVE AGAINST HEPATITIS B VIRUS (HBV)
CU20200045A7 (en) 2017-11-02 2021-03-11 Aicuris Gmbh & Co Kg PYRAZOLO-PIPERIDINE SUBSTITUTE INDEOL-2-CARBOXAMID DERIVATIVES ACTIVE AGAINST HEPATITIS B VIRUS (HBV)
TW201936192A (en) 2017-12-06 2019-09-16 美商因那塔製藥公司 Hepatitis B antiviral agents
US10428070B2 (en) 2017-12-06 2019-10-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
EP3728282B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
KR102492187B1 (en) 2017-12-20 2023-01-27 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 3'3' cyclic dinucleotides with phosphonate linkages that activate STING adapter proteins
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
MX2020008404A (en) 2018-02-13 2020-09-25 Gilead Sciences Inc Pd-1/pd-l1 inhibitors.
JP2021513981A (en) 2018-02-16 2021-06-03 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ JAK1 pathway inhibitors for the treatment of cytokine-related disorders
KR102526964B1 (en) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Substituted pyrrolizine compounds as HBV replication inhibitors
AU2019235522A1 (en) 2018-03-14 2020-09-03 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
WO2019191166A1 (en) 2018-03-29 2019-10-03 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
MX2022012285A (en) 2018-03-30 2023-08-15 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors.
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI818007B (en) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-cyclic dinucleotides
EP3774832A1 (en) 2018-04-06 2021-02-17 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotides
TW202005654A (en) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2'2'-cyclic dinucleotides
TW201945388A (en) 2018-04-12 2019-12-01 美商精密生物科學公司 Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis B virus genome
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
TW202014193A (en) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 2’3’-cyclic dinucleotides comprising carbocyclic nucleotide
US11098027B2 (en) 2018-07-06 2021-08-24 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
KR102629921B1 (en) 2018-07-06 2024-01-31 길리애드 사이언시즈, 인코포레이티드 Therapeutic Heterocyclic Compounds
CN108947996B (en) * 2018-07-12 2022-01-18 山东大学 Dihydropyrimidine-sulfonamide derivative and preparation method and application thereof
AU2019301811B2 (en) 2018-07-13 2022-05-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
US11053235B2 (en) 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
US10865211B2 (en) 2018-09-21 2020-12-15 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
WO2020086533A1 (en) 2018-10-22 2020-04-30 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
BR112021008255A2 (en) 2018-10-31 2021-08-03 Gilead Sciences, Inc. substituted 6-azabenzimidazole compounds as hpk1 inhibitors
KR20210084579A (en) 2018-10-31 2021-07-07 길리애드 사이언시즈, 인코포레이티드 Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity
EP3873488A4 (en) 2018-10-31 2022-08-03 The University of Sydney Compositions and methods for treating viral infections
AR117189A1 (en) 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg DERIVATIVES OF 6,7-DIHIDRO-4H-PIRAZOLO [1,5-A] PIRAZIN INDOL-2-CARBOXAMIDAS ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV)
AR117188A1 (en) 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg DERIVATIVES OF UREA 6,7-DIHIDRO-4H-PIRAZOLO [1,5-A] PYRAZINES ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV)
AR116946A1 (en) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg DERIVATIVES OF UREA 6,7-DIHIDRO-4H-PIRAZOLO [4,3-C] PYRIDINES ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV)
AU2019373679A1 (en) 2018-11-02 2021-05-27 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4H-thiazolo(5,4-c)pyridines active against the hepatitis B virus (HBV)
UY38436A (en) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg NEW 6,7-DIHYDRO-4H-PYRAZOLE [1,5-A] PYRAZININDOL-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
UY38435A (en) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg NEW UREA 6,7-DIHIDRO-4H-PIRAZOL [1,5-A] PIRAZINAS ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV)
UY38483A (en) 2018-11-21 2020-06-30 Enanta Pharm Inc HETEROCYCLES FUNCTIONALIZED AS ANTIVIRAL AGENTS
TW202035412A (en) * 2018-12-20 2020-10-01 比利時商健生藥品公司 Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
US11096931B2 (en) 2019-02-22 2021-08-24 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
KR20210137517A (en) 2019-03-07 2021-11-17 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 2'3'-cyclic dinucleotides and prodrugs thereof
CA3129011C (en) 2019-03-07 2023-12-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
CA3130596A1 (en) 2019-03-25 2020-10-01 F. Hoffmann-La Roche Ag Solid forms of a compound of hbv core protein allosteric modifier
TW202210480A (en) 2019-04-17 2022-03-16 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TW202212339A (en) 2019-04-17 2022-04-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
SG11202111198QA (en) 2019-04-30 2021-11-29 Aicuris Gmbh & Co Kg Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
CA3138380A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel oxalyl piperazines active against the hepatitis b virus (hbv)
CU20210088A7 (en) 2019-04-30 2022-06-06 Aicuris Gmbh & Co Kg COMPOUNDS SUBSTITUTED DERIVATIVES OF INDOL-2-CARBOXAMIDES ACTIVE AGAINST HEPATITIS B VIRUS (HBV)
WO2020221816A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)
AR119732A1 (en) 2019-05-06 2022-01-05 Janssen Sciences Ireland Unlimited Co AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES
TWI826690B (en) 2019-05-23 2023-12-21 美商基利科學股份有限公司 Substituted eneoxindoles and uses thereof
EP3975996A1 (en) 2019-05-24 2022-04-06 Assembly Biosciences, Inc. Pharmaceutical compositions for the treatment of hbv
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
CA3140708A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
JP7295283B2 (en) 2019-06-25 2023-06-20 ギリアード サイエンシーズ， インコーポレイテッド FLT3L-FC fusion proteins and methods of use
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
EP4003997A4 (en) * 2019-07-31 2023-08-02 Janssen Sciences Ireland Unlimited Company Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
EP4037708A1 (en) 2019-09-30 2022-08-10 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
US20230031465A1 (en) 2019-12-06 2023-02-02 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
EP4077305A4 (en) * 2019-12-20 2024-01-10 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
CN115605493A (en) 2020-03-20 2023-01-13 吉利德科学公司（Us） Prodrugs of4'-C-substituted-2-halo-2' -deoxyadenosine nucleosides and methods of making and using the same
IL297305A (en) 2020-04-22 2022-12-01 Assembly Biosciences Inc 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2021216642A1 (en) 2020-04-22 2021-10-28 Assembly Biosciences, Inc. Pyrazole carboxamide compounds for treatment of hbv
WO2021216661A1 (en) 2020-04-22 2021-10-28 Assembly Biosciences, Inc. Pyrazole carboxamide compounds for treatment of hbv
WO2021216660A1 (en) 2020-04-22 2021-10-28 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
PE20231102A1 (en) 2020-06-02 2023-07-19 Incyte Corp PROCESSES FOR PREPARING A JAK1 INHIBITOR
US20220119426A1 (en) 2020-08-07 2022-04-21 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
WO2022052923A1 (en) * 2020-09-08 2022-03-17 和博医药有限公司 Dihydropyrimidine compound and application thereof
TWI815194B (en) 2020-10-22 2023-09-11 美商基利科學股份有限公司 INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE
WO2022166923A1 (en) 2021-02-05 2022-08-11 和博医药有限公司 Phenyldihydropyrimidine compound and use thereof
CN113135921B (en) * 2021-04-26 2022-06-17 山东大学 Dihydropyrimidine-spiro derivative and preparation method and application thereof
CN113512035B (en) * 2021-04-26 2023-11-24 山东大学 Dihydropyrimidine-pomalidomide conjugate, and preparation method and application thereof
CA3217107A1 (en) 2021-05-13 2022-11-17 Daniel J. CLOUTIER Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
CN117355531A (en) 2021-06-23 2024-01-05 吉利德科学公司 Diacylglycerol kinase modulating compounds
CA3220923A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117396478A (en) 2021-06-23 2024-01-12 吉利德科学公司 Diacylglycerol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023069547A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023069545A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023069544A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023164186A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164179A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164183A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164181A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10012823A1 (en) * 2000-03-16 2001-09-20 Bayer Ag New alkyl-6-aminoalkyl-dihydropyrimidine-5-carboxylate derivatives, useful for the treatment of viral, especially hepatitis B, infections
DE10013126A1 (en) * 2000-03-17 2001-09-20 Bayer Ag New 6-aminoalkyl-dihydropyrimidine-5-carboxylate ester derivatives, useful as antiviral agents having strong activity against hepatitis B virus and low cytotoxicity
WO2006033995A2 (en) 2004-09-16 2006-03-30 Valeant Research And Development Thiazolidin-4-ones having anti-hepatitis b activity
WO2008154819A1 (en) * 2007-06-18 2008-12-24 Zhang, Zhongneng Carbethoxy-substituted thiazolyl dihydropyrimidines
MY178867A (en) * 2011-11-30 2020-10-21 Hoffmann La Roche New bicyclic dihydroisoquinoline-1-one derivatives
PE20150776A1 (en) * 2012-09-10 2015-05-21 Hoffmann La Roche 6-AMINO ACID-HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
JP6533217B2 (en) * 2013-05-17 2019-06-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 6-Bridged Heteroaryldihydropyrimidines for the Treatment and Prevention of Hepatitis B Virus Infection
EP3114128B1 (en) * 2014-03-07 2019-01-02 F. Hoffmann-La Roche AG Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection

Also Published As

Publication number Publication date
US9758530B2 (en) 2017-09-12
AU2014267198A1 (en) 2015-11-05
JP6533217B2 (en) 2019-06-19
PH12015502443A1 (en) 2016-02-22
EP2997032B1 (en) 2018-07-25
CN105209470A (en) 2015-12-30
EP2997032A1 (en) 2016-03-23
JP2016518432A (en) 2016-06-23
HK1219480A1 (en) 2017-04-07
WO2014184328A1 (en) 2014-11-20
TW201512193A (en) 2015-04-01
CR20150611A (en) 2015-12-07
EA201592126A1 (en) 2016-05-31
CN105209470B (en) 2018-02-06
CL2015003298A1 (en) 2016-06-17
CA2911214A1 (en) 2014-11-20
US9266904B2 (en) 2016-02-23
MX2015015692A (en) 2016-03-04
US20140343032A1 (en) 2014-11-20
PE20151951A1 (en) 2015-12-26
US20160122363A1 (en) 2016-05-05
ZA201507840B (en) 2017-11-29
BR112015028873A2 (en) 2017-07-25

Similar Documents

Publication Publication Date Title
HK1219480A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection 6-
HRP20190352T1 (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
HK1223931A1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
HK1251220A1 (en) Novel tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
HK1203944A1 (en) 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection 4--
HK1251554A1 (en) Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
HK1248711A1 (en) Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
IL244431A0 (en) Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection
HK1210152A1 (en) 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection 6-
HK1210022A1 (en) Methods for the treatment of hepatitis b and hepatitis d infections
HK1231402A1 (en) Methods for the treatment of hepatitis b and hepatitis d virus infections b d
PL3137078T3 (en) Treatment of hepatitis delta virus infection
EP2969006A4 (en) Compositions and methods for treating an immunodeficiency virus infection
ZA201604784B (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection